|
1
|
Kashyap D, Pal D, Sharma R, Garg VK, Goel
N, Koundal D, Zaguia A, Koundal S and Belay A: Global increase in
breast cancer incidence: Risk Factors and Preventive Measures.
BioMed Res Int. 2022:96054392022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
3
|
Breast Cancer, . https://www.who.int/es/news-room/fact-sheets/detail/breast-cancerJanuary
16–2023(In Spanish).
|
|
4
|
Wilkinson L and Gathani T: Understanding
breast cancer as a global health concern. Br J Radiol.
95:202110332022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu
ZY, Shi W, Jiang J, Yao PP and Zhu HP: Risk factors and preventions
of breast cancer. Int J Biol Sci. 13:1387–1397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Early Breast Cancer Trialists' and
Collaborative Group (EBCTCG), . Aromatase inhibitors versus
tamoxifen in early breast cancer: Patient-level meta-analysis of
the randomised trials. Lancet. 386:1341–1352. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
DeSantis C, Jemal A and Ward E:
Disparities in breast cancer prognostic factors by race, insurance
status, and education. Cancer Causes Control. 21:1445–1450.
2010.PubMed/NCBI
|
|
8
|
Godina C, Ottander E, Tryggvadottir H,
Borgquist S, Isaksson K and Jernström H: Prognostic impact of
menopausal hormone therapy in breast cancer differs according to
tumor characteristics and treatment. Front Oncol. 10:802020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cagnacci A and Venier M: The controversial
history of hormone replacement therapy. Medicina (Mex). 55:6022019.
View Article : Google Scholar
|
|
10
|
Grodstein F, Stampfer MJ, Colditz GA,
Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE,
Hunter DJ, et al: Postmenopausal hormone therapy and mortality. N
Engl J Med. 336:1769–1776. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Falkeborn M, Persson I, Adami HO,
Bergström R, Eaker E, Lithell H, Mohsen R and Naessén T: The risk
of acute myocardial infarction after oestrogen and
oestrogen-progestogen replacement. Br J Obstet Gynaecol.
99:821–828. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kiel DP, Felson DT, Anderson JJ, Wilson PW
and Moskowitz MA: Hip fracture and the use of estrogens in
postmenopausal women. The Framingham study. N Engl J Med.
317:1169–1174. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weiss NS, Ure CL, Ballard JH, Williams AR
and Daling JR: Decreased risk of fractures of the hip and lower
forearm with postmenopausal use of estrogen. N Engl J Med.
303:1195–1198. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ziel HK and Finkle WD: Increased risk of
endometrial carcinoma among users of conjugated estrogens. N Engl J
Med. 293:1167–1170. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rossouw JE, Anderson GL, Prentice RL,
LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA,
Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus
progestin in healthy postmenopausal women: Principal results From
the Women's Health Initiative randomized controlled trial. JAMA.
288:321–333. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ravdin PM, Cronin KA, Howlader N, Berg CD,
Chlebowski RT, Feuer EJ, Edwards BK and Berry DA: The decrease in
breast-cancer incidence in 2003 in the United States. N Engl J Med.
356:1670–1674. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Jong-van den Berg LTW, Faber A and van
den Berg PB: HRT use in 2001 and 2004 in The Netherlands-a world of
difference. Maturitas. 54:193–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Silverman BG and Kokia ES: Use of hormone
replacement therapy, 1998–2007: Sustained impact of the Women's
Health Initiative findings. Ann Pharmacother. 43:251–258. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Menon U, Burnell M, Sharma A,
Gentry-Maharaj A, Fraser L, Ryan A, Parmar M, Hunter M and Jacobs
I; UKCTOCS Group, : Decline in use of hormone therapy among
postmenopausal women in the United Kingdom. Menopause. 14:462–467.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baladé Martínez L, Montero Corominas D and
Macías Saint-Gerons D: Use of hormone replacement therapy in Spain:
Trends in the 2000–2014 period. Med Clin (Barc). 147:287–292.
2016.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vankrunkelsven P, Kellen E, Lousbergh D,
Cloes E, Op de Beeck L, Faes C, Bruckers L, Mertens R, Coebergh JW,
Van Leeuwen FE and Buntinx F: Reduction in hormone replacement
therapy use and declining breast cancer incidence in the Belgian
province of Limburg. Breast Cancer Res Treat. 118:425–432. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Séradour B, Allemand H, Weill A and
Ricordeau P: Sustained lower rates of breast cancer incidence in
France in 2007. Breast Cancer Res Treat. 121:799–800. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumle M: Declining breast cancer incidence
and decreased HRT use. Lancet. 372:608–610. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zbuk K and Anand SS: Declining incidence
of breast cancer after decreased use of hormone-replacement
therapy: Magnitude and time lags in different countries. J
Epidemiol Community Health. 66:1–7. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gompel A and Santen RJ: Hormone therapy
and breast cancer risk 10 years after the WHI. Climacteric.
15:241–249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lobo RA: Hormone-replacement therapy:
Current thinking. Nat Rev Endocrinol. 13:220–231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu X, Zhou S, Wang J, Zhang Q, Hou J, Zhu
L, He Y, Zhao J and Zhong S: Hormone replacement therapy and breast
cancer survival: A systematic review and meta-analysis of
observational studies. Breast Cancer. 24:643–657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: PRISMA 2020 Statement: An updated guideline for
reporting systematic reviews. Rev Esp Cardiol (Engl Ed).
74:790–799. 2021.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wells GA, Shea B, O'Connell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in
meta-analyses. 2011.https://www.ohri.ca/programs/clinical_epidemiology/oxford.aspJanuary
19–2023
|
|
30
|
Higgins JPT, Morgan RL, Rooney AA, Taylor
KW, Thayer KA, Raquel A. Silva RA, Courtney Lemeris C, Akl EA, et
al: A tool to assess risk of bias in non-randomized follow-up
studies of exposure effects (ROBINS-E). Environment International.
186:1086022024.Launch version, 20 June, 2023. https://www.riskofbias.info/welcome/robinse-toolJuly
3–2023 View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Egger M, Smith GD, Schneider M and Minder
C: Bias in meta-analysis detected by a simple, graphical test. BMJ.
315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Persson I, Yuen J, Bergkvist L and
Schairer C: Cancer incidence and mortality in women receiving
estrogen and estrogen-progestin replacement therapy-long-term
follow-up of a Swedish cohort. Int J Cancer. 67:327–332. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hunt K, Vessey M and McPherson K:
Mortality in a cohort of Long-term users of hormone replacement
therapy: An updated analysis. Br J Obstet Gynaecol. 97:1080–1086.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rosenberg LU, Granath F, Dickman PW,
Einarsdóttir K, Wedrén S, Persson I and Hall P: Menopausal hormone
therapy in relation to breast cancer characteristics and prognosis:
A cohort study. Breast Cancer Res. 10:R782008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hellmann SS, Thygesen LC, Tolstrup JS and
Grønbæk M: Modifiable risk factors and survival in women diagnosed
with primary breast cancer: Results from a prospective cohort
study. Eur J Cancer Prev. 19:366–373. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Newcomb PA, Egan KM, Trentham-Dietz A,
Titus-Ernstoff L, Baron JA, Hampton JM, Stampfer MJ and Willett WC:
Prediagnostic use of hormone therapy and mortality after breast
cancer. Cancer Epidemiol Biomarkers Prev. 17:864–871. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Christante D, Pommier S, Garreau J, Muller
P, LaFleur B and Pommier R: Improved breast cancer survival among
hormone replacement therapy users is durable after 5 years of
additional follow-up. Am J Surg. 196:505–511. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Manson JE, Aragaki AK, Rossouw JE,
Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV,
Thomson CA, Margolis KL, et al: Menopausal hormone therapy and
Long-Term All-Cause and Cause-Specific mortality: The Women's
Health initiative randomized trials. Obstet Gynecol Surv. 73:22–24.
2018. View Article : Google Scholar
|
|
39
|
Fletcher AS, Erbas B, Kavanagh AM, Hart S,
Rodger A and Gertig DM: Use of hormone replacement therapy (HRT)
and survival following breast cancer diagnosis. Breast. 14:192–200.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schuetz F, Diel IJ, Pueschel M, von Holst
T, Solomayer EF, Lange S, Sinn P, Bastert G and Sohn C: Reduced
incidence of distant metastases and lower mortality in 1072
patients with breast cancer with a history of hormone replacement
therapy. Am J Obstet Gynecol. 196:342.e1–e9. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ettinger B, Friedman GD and Quesenberry CP
Jr: Reduced mortality associated with Long-Term postmenopausal
estrogen therapy. Obstet Gynecol. 87:6–12. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schairer C, Gail M, Byrne C, Rosenberg PS,
Sturgeon SR, Brinton LA and Hoover RN: Estrogen replacement therapy
and breast cancer survival in a large screening study. J Natl
Cancer Inst. 91:264–270. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sener SF, Winchester DJ, Winchester DP, Du
H, Barrera E, Bilimoria M, Krantz S and Rabbitt S: The effects of
hormone replacement therapy on postmenopausal breast cancer biology
and survival. Am J Surg. 197:403–407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Reding KW, Doody DR, McTiernan A, Hsu L,
Davis S, Daling JR, Porter PL and Malone KE: Age-related variation
in the relationship between menopausal hormone therapy and the risk
of dying from breast cancer. Breast Cancer Res Treat. 126:749–761.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stahlberg C, Lynge E, Andersen ZJ, Keiding
N, Ottesen B, Rank F, Hundrup YA, Obel EB and Pedersen AT: Breast
cancer incidence, case-fatality and breast cancer mortality in
Danish women using hormone replacement therapy-a prospective
observational study. Int J Epidemiol. 34:931–935. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chlebowski RT, Manson JE, Anderson GL,
Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC,
Wactawski-Wende J, Chen C, et al: Estrogen plus progestin and
breast cancer incidence and mortality in the Women's health
initiative observational study. J Natl Cancer Inst. 105:526–355.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Holm M, Olsen A, Kroman N and Tjønneland
A: Lifestyle influences on the association between pre-diagnostic
hormone replacement therapy and breast cancer prognosis-Results
from the Danish ‘Diet, Cancer and Health’ prospective cohort.
Maturitas. 79:442–448. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Obi N, Heinz J, Seibold P, Vrieling A,
Rudolph A, Chang-Claude J, Berger J and Flesch-Janys D:
Relationship between menopausal hormone therapy and mortality after
breast cancer The MARIEplus study, a prospective case cohort. Int J
Cancer. 138:2098–2108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen W, Petitti DB and Geiger AM:
Mortality following development of breast cancer while using
oestrogen or oestrogen plus progestin: A computer record-linkage
study. Br J Cancer. 93:392–398. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pentti K, Honkanen R, Tuppurainen MT,
Sandini L, Kröger H and Saarikoski S: Hormone replacement therapy
and mortality in 52- to 70-year-old women: The Kuopio osteoporosis
risk factor and prevention study. Eur J Endocrinol. 154:101–107.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Norman SA, Weber AL, Localio AR,
Marchbanks PA, Ursin G, Strom BL, Weiss LK, Burkman RT, Bernstein
L, Deapen DM, et al: Hormone therapy and fatal breast cancer.
Pharmacoepidemiol Drug Saf. 19:440–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Beral V and Million Women Study
Collaborators, . Breast cancer and hormone-replacement therapy in
the Million Women Study. Lancet. 362:419–427. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sellers TA, Mink PJ, Cerhan JR, Zheng W,
Anderson KE, Kushi LH and Folsom AR: The role of hormone
replacement therapy in the risk for breast cancer and total
mortality in women with a family history of breast cancer. Ann
Intern Med. 127:973–980. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bonnier P, Bessenay F, Sasco AJ, Beedassy
B, Lejeune C, Romain S, Charpin C, Piana L and Martin PM: Impact of
menopausal hormone-replacement therapy on clinical and laboratory
characteristics of breast cancer. Int J Cancer. 79:278–282. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sturgeon SR, Schairer C, Brinton LA,
Pearson T and Hoover RN: Evidence of a healthy estrogen user
survivor effect. Epidemiology. 6:227–231. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Willis DB, Calle EE, Miracle-McMahill HL
and Heath CW Jr: Estrogen replacement therapy and risk of fatal
breast cancer in a prospective cohort of postmenopausal women in
the United States. Cancer Causes Control. 7:449–457.
1996.PubMed/NCBI
|
|
57
|
Magnusson C, Holmberg L, Nordén T,
Lindgren A and Persson I: Prognostic characteristics in breast
cancers after hormone replacement therapy. Breast Cancer Res Treat.
38:325–334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Alonso-Molero J, Gómez-Acebo I, Llorca J,
Lope-Carvajal V, Amiano P, Guevara M, Martín V, Castaño-Vinyals G,
Fernández-Ortiz M, Obón-Santacana M, et al: Effect of the use of
prediagnosis hormones on breast cancer prognosis: MCC-Spain study.
Menopause. 29:1315–1322. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sourander L, Rajala T, Räihä I, Mäkinen J,
Erkkola R and Helenius H: Cardiovascular and cancer morbidity and
mortality and sudden cardiac death in postmenopausal women on
oestrogen replacement therapy (ERT). Lancet. 352:1965–1969. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pocobelli G, Newcomb PA, Li CI, Cook LS,
Barlow WE and Weiss NS: Fatal breast cancer risk in relation to use
of unopposed estrogen and combined hormone therapy. Breast Cancer
Res Treat. 145:439–447. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jernström H, Frenander J, Fernö M and
Olsson H: Hormone replacement therapy before breast cancer
diagnosis significantly reduces the overall death rate compared
with never-use among 984 breast cancer patients. Br J Cancer.
80:1453–1458. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cheek J, Lacy J, Toth-Fejel S, Morris K,
Calhoun K and Pommier RF: The impact of hormone replacement therapy
on the detection and stage of breast cancer. Arch Surg.
137:1015–1021. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chlebowski RT, Anderson GL, Aragaki AK,
Manson JE, Stefanick ML, Pan K, Barrington W, Kuller LH, Simon MS,
Lane D, et al: Association of menopausal hormone therapy with
breast cancer incidence and mortality during Long-term Follow-up of
the Women's Health initiative randomized clinical trials. JAMA.
324:369–380. 2020. View Article : Google Scholar : PubMed/NCBI
|
